Literature DB >> 36098872

Teserpaturev/G47Δ: First Approval.

James E Frampton1.   

Abstract

Teserpaturev/G47Δ (Delytact®) is a third-generation (triple-mutated) recombinant oncolytic herpes simplex virus type 1 being developed by Daiichi Sankyo Co., Ltd. for the treatment of certain solid cancers. Teserpaturev/G47Δ has been approved for the treatment of malignant glioma in Japan and is currently in clinical development for the treatment of prostate cancer (phase II), malignant pleural mesothelioma (phase I) and recurrent olfactory neuroblastoma (phase I). This article summarizes the milestones in the development of teserpaturev/G47Δ leading to this first approval for the treatment of malignant glioma.
© 2022. The Author(s), under exclusive licence to Springer Nature Switzerland AG.

Entities:  

Mesh：

Year:  2022        PMID： 36098872     DOI： 10.1007/s40259-022-00553-7

Source DB:  PubMed          Journal:  BioDrugs        ISSN： 1173-8804            Impact factor:   7.744


  2 in total

1.  Transient fasting enhances replication of oncolytic herpes simplex virus in glioblastoma.

Authors:  Shinichi Esaki; Samuel D Rabkin; Robert L Martuza; Hiroaki Wakimoto
Journal:  Am J Cancer Res       Date:  2016-01-15       Impact factor: 6.166

2.  Intratumoral oncolytic herpes virus G47∆ for residual or recurrent glioblastoma: a phase 2 trial.

Authors:  Tomoki Todo; Hirotaka Ito; Yasushi Ino; Hiroshi Ohtsu; Yasunori Ota; Junji Shibahara; Minoru Tanaka
Journal:  Nat Med       Date:  2022-07-21       Impact factor: 87.241
  2 in total
  1 in total

Review 1.  Improving cancer immunotherapy by rationally combining oncolytic virus with modulators targeting key signaling pathways.

Authors:  Zhi Zhu; A J Robert McGray; Weijian Jiang; Binfeng Lu; Pawel Kalinski; Zong Sheng Guo
Journal:  Mol Cancer       Date:  2022-10-12       Impact factor: 41.444
  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.